Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical

Drug Profile

Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical

Alternative Names: Abilify; Abilify Maintena; Abilify MyCite; ABILIFY MYCITE; Abilitat; Ao Pai; Aripiprazole depot - Otsuka Pharmaceutical/Lundbeck; Aripiprazole ECER tablets; Arlemide; OPC-14597; OPC-14597 IMD; OPC-31

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Bristol-Myers Squibb; Indiana University; Lundbeck A/S; Otsuka Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor partial agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autistic disorder; Bipolar disorders; Gilles de la Tourette's syndrome; Major depressive disorder; Schizophrenia
  • Phase III Agitation; Pervasive child development disorders
  • Discontinued Attention-deficit hyperactivity disorder; Psychotic disorders

Most Recent Events

  • 12 Jun 2018 Otsuka Pharmaceutical completes a phase I trial in Schizophrenia in USA (NCT03150771)
  • 04 Apr 2018 Otsuka Beijing Research Institute plans a phase III trial for Autistic Disorder (In children, In adolescents) in April 2018 , (NCT03487770)
  • 04 Apr 2018 Otsuka Beijing Research Institute plans a phase III trial for Tourette's Disorder (In children, In adolescents) in April 2018 (NCT03487783)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top